Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sandra Richman"'
Autor:
Tuan Dong-Si, Amy Gangadharan, James D. McIninch, Madé Wenten, Thomas Weber, Sarah Gheuens, Nancy Richert, Gary Bloomgren, Jeffrey Philip, Sandra Richman, Carmen Bozic, David B. Clifford, Shoibal Datta
Publikováno v:
Journal of Neurovirology
Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of this analysis was to examine factors predicting survival in a large na
Publikováno v:
The Lancet. Neurology. 16(11)
Previous estimates of risk of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis receiving natalizumab were stratified by three risk factors: anti-John Cunningham virus (JCV) antibodies in serum, previous immunosuppr
Publikováno v:
European Journal of Neurology. 21:299-304
Background and purpose Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of JC virus (JCV) infection due to combined host and viral factors. Anti-JCV antibodies provide a means to assess JCV exposure and stratify PML risk. Th
Publikováno v:
BMC Neurology
Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab are currently advised to balance the po
Autor:
James V. Scanlon, Meena Subramanyam, Tatiana Plavina, Alfred Sandrock, Gary Bloomgren, Sandra Richman, Amy Natarajan, Carmen Bozic
Publikováno v:
Annals of Neurology. 70:742-750
Objective: A study was undertaken to define the prevalence of anti-JC virus (JCV) antibodies in multiple sclerosis (MS) patients and to evaluate the analytical false-negative rate of a 2-step anti-JC virus antibody assay. Methods: STRATIFY-1 is an on
Autor:
Michaela Lerner, Margot Brickelmaier, Mary Crossman, Darren P. Baker, Ivan Nestorov, Shifang Liu, Meena Subramanyam, Larisa Miller, Gudarz Davar, Michael Panzara, R. B. Pepinsky, Xiao Hu, Ying Zhu, Sandra Richman, Kenneth Olivier, Gabrielle Glick, Stacy Hitchman, Robert S. Gronke
Publikováno v:
Journal of Interferon & Cytokine Research. 30:777-785
Multiple sclerosis is a chronic autoimmune disease of the central nervous system for which a number of disease-modifying therapies are available, including interferon beta (Avonex®, Rebif®, and Betaseron/Betaferon®), glatiramer acetate (Copaxone®
Autor:
Sarah Gheuens, Madé Wenten, Jeffrey Philip, Mike P. Wattjes, Tuan Dong-Si, Nancy Richert, Shoibal Datta, Gary Bloomgren, Sandra Richman, Carmen Bozic, James D. McIninch
Publikováno v:
Dong-Si, T, Richman, S, Wattjes, M P, Wenten, M, Gheuens, S, Philip, J, Datta, S, McIninch, J, Bozic, C, Bloomgren, G & Richert, N 2014, ' Outcome and survival of asymptomatic PML in natalizumab-treated MS patients ', Annals of Clinical and Translational Neurology, vol. 1, no. 10, pp. 755-764 . https://doi.org/10.1002/acn3.114
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, 1(10), 755-764. John Wiley and Sons Ltd
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, 1(10), 755-764. John Wiley and Sons Ltd
Objective As of 3 September 2013, 399 cases of natalizumab-associated progressive multifocal leukoencephalopathy (PML) were confirmed in multiple sclerosis (MS) patients. We evaluated outcomes of natalizumab-treated MS patients who were asymptomatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1469d66535118335ff823a97753ebc3
https://research.vumc.nl/en/publications/e7874827-aa2f-40b1-a80c-60d281c73fc1
https://research.vumc.nl/en/publications/e7874827-aa2f-40b1-a80c-60d281c73fc1
Autor:
Sophia Lee, Sandra Richman, Meena Subramanyam, Carmen Bozic, Susan Goelz, James V. Scanlon, Amy Natarajan, Tatiana Plavina, Gary Bloomgren, Christophe Hotermans, Alfred Sandrock
Publikováno v:
The New England journal of medicine. 366(20)
Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of three risk factors: positive status with respect to
Autor:
Robert S. Gronke, Xiao Hu, Mary Crossman, Ivan Nestorov, Shifang Liu, Stacy Hitchman, Ying Zhu, Larisa Miller, Mark Rogge, Sandra Richman, Meena Subramanyam, Gabrielle Glick, Gudarz Davar, Darren P. Baker
This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers. Two randomized, blinded phase I studies were conducted: a single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3920079ffe96ab946fdc0aa66b72375
https://www.bib.irb.hr/510550
https://www.bib.irb.hr/510550
Autor:
Sandra Richman, Carmen Bozic, Sophia Lee, Gary Bloomgren, James V. Scanlon, Christophe Hotermans, Alfred Sandrock, Meena Subramanyam, Tatiana Plavina, Amy Natarajan
Publikováno v:
Neurology. 78:S41.001-S41.001
Objective: To quantify progressive multifocal leukoencephalopathy (PML) risk in multiple sclerosis (MS) patients considering or receiving natalizumab using three risk factors: anti-JC virus (JCV) antibody positive serostatus, prior immunosuppressant